NRIX
Income statement / Annual
Last year (2023), Nurix Therapeutics, Inc.'s total revenue was $76.99 M,
an increase of 99.31% from the previous year.
In 2023, Nurix Therapeutics, Inc.'s net income was -$143.95 M.
See Nurix Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
11/30/2023 |
11/30/2022 |
11/30/2021 |
11/30/2020 |
11/30/2019 |
11/30/2018 |
| Operating Revenue |
$76.99 M
|
$38.63 M
|
$29.75 M
|
$17.82 M
|
$31.12 M
|
$37.45 M
|
| Cost of Revenue |
$189.15 M |
$10.81 M |
$6.08 M |
$66.49 M |
$45.03 M |
$40.51 M |
| Gross Profit |
-$112.16 M |
$27.82 M |
$23.67 M |
-$48.67 M |
-$13.91 M |
-$3.07 M |
| Gross Profit Ratio |
-1.46 |
0.72 |
0.8 |
-2.73 |
-0.45 |
-0.08 |
| Research and Development
Expenses |
$189.15 M
|
$184.50 M
|
$116.43 M
|
$66.49 M
|
$45.03 M
|
$40.51 M
|
| General & Administrative
Expenses |
$42.90 M
|
$38.00 M
|
$31.20 M
|
$16.31 M
|
$8.33 M
|
$6.67 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$42.90 M
|
$38.00 M
|
$31.20 M
|
$16.31 M
|
$8.33 M
|
$6.67 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$232.05 M |
$222.49 M |
$147.64 M |
$82.80 M |
$53.35 M |
$47.19 M |
| Cost And Expenses |
$232.05 M |
$222.49 M |
$147.64 M |
$82.80 M |
$53.35 M |
$47.19 M |
| Interest Income |
$11.12 M |
$3.51 M |
$823,000.00 |
$1.21 M |
$776,000.00 |
$818,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$13.65 M
|
$10.81 M
|
$6.08 M
|
$2.18 M
|
$2.35 M
|
$2.99 M
|
| EBITDA |
-$141.41 M
|
-$173.06 M
|
-$111.80 M
|
-$62.80 M
|
-$19.88 M
|
-$6.75 M
|
| EBITDA Ratio |
-1.84 |
-4.76 |
-3.96 |
-3.65 |
-0.64 |
-0.18 |
| Operating Income Ratio
|
-2.01
|
-4.76
|
-3.96
|
-3.65
|
-0.71
|
-0.26
|
| Total Other
Income/Expenses Net |
$11.12 M
|
$3.51 M
|
$823,000.00
|
$1.21 M
|
$776,000.00
|
$818,000.00
|
| Income Before Tax |
-$143.95 M |
-$180.36 M |
-$117.06 M |
-$63.78 M |
-$21.46 M |
-$8.92 M |
| Income Before Tax Ratio
|
-1.87
|
-4.67
|
-3.93
|
-3.58
|
-0.69
|
-0.24
|
| Income Tax Expense |
$0.00 |
-$14.32 M |
$131,000.00 |
-$20.54 M |
$239,000.00 |
$507,000.00 |
| Net Income |
-$143.95 M |
-$166.05 M |
-$117.19 M |
-$43.24 M |
-$21.70 M |
-$9.43 M |
| Net Income Ratio |
-1.87 |
-4.3 |
-3.94 |
-2.43 |
-0.7 |
-0.25 |
| EPS |
-2.65 |
-3.42 |
-2.73 |
-2.76 |
-0.56 |
-0.59 |
| EPS Diluted |
-2.65 |
-3.42 |
-2.73 |
-2.76 |
-0.56 |
-0.59 |
| Weighted Average Shares
Out |
$54.34 M
|
$48.61 M
|
$42.90 M
|
$15.67 M
|
$38.85 M
|
$16.11 M
|
| Weighted Average Shares
Out Diluted |
$54.34 M
|
$48.61 M
|
$42.90 M
|
$15.67 M
|
$38.85 M
|
$16.11 M
|
| Link |
|
|
|
|
|
|
